Eliaz Therapeutics
Eliaz Therapeutics, with a valuation of $49.5 million, is raising funds on Wefunder. The business has created a life-saving medical device to fight against sepsis. Eliaz Therapeutics’ XGal-3 is designed to halt sepsis progression by targeting Galectin-3, a protein that drives the deadly inflammatory process. The innovative technology behind XGal-3 is protected by 60 patents across 34 countries and has potential applications beyond sepsis, including cancer and kidney disease. Isaac Eliaz founded Eliaz Therapeutics in September 2015. The current crowdfunding campaign has a minimum target of $50,000 and a maximum target of $1.24 million. The campaign proceeds will be used for product development, QA and regulatory activities, ligand development, clinical and strategy readiness, and general and administrative expenses.
Investment Overview
Raised: $164,561
Deal Terms
Total Commitments ($USD)
- Platform
- Wefunder
- Start Date
- 11/08/2024
- Close Date
- 04/30/2025
$50,000
$1,235,000
$250
SAFE
Seed
RegCF
$39,600,000
$49,500,000
10%
Company & Team
Company
- Year Founded
- 2015
- Industry
- Healthcare & Pharmaceuticals
- Tech Sector
- Distribution Model
- B2B2C
- Margin
- Medium
- Capital Intensity
- High
Upgrade to gain access
-
$12.50 /month
billed annually - Free portfolio tracking, data-driven ratings, AI analysis and reports
- Plan Includes:
- Everything in Free, plus
- Company specific
Kingscrowd ratings and analyst reports
- Deal explorer and side-by-side comparison
- Startup exit and failure tracking
- Startup market filters and historical industry data
- Advanced company search ( with ratings)
- Get Edge Annual
Edge
Ratings 
Company Funding & Growth
Funding history
- Total Prior Capital Raised
- $3,400,000
- Grants
- $224,577
- VC Backed?
- Yes
| Close Date | Platform | Valuation | Total Raised | Security Type | Status | Reg Type |
|---|---|---|---|---|---|---|
| 04/30/2025 | Wefunder | $49,500,000 | $164,561 | SAFE | Active | RegCF |